89 results about "Lipoprotein cholesterol" patented technology

The invention discloses a polysaccharide composition for treating hyperlipemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing phellinus linteus linteus, inonotus hispidus and boletus coratus and then performing water extraction. The polysaccharide composition provided by the invention can be used for reducing fat vacuolation and fat index, reducing the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increasing the content of high-density lipoprotein cholesterol by inhibiting the increase of weight and blood sugar of a hyperlipidemia mouse; the composition and abundance of intestinal flora are regulated and controlled, the intestinal flora disorder phenomenon is improved, the effect is better than that of single polysaccharide, and a new direction is provided for treatment for assisting blood sugar reduction.

The invention relates to N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition and application thereof, and relates to the technical field of biological medicines. According to the application disclosed by the invention, the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid is found to have the effects of reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum and increasing high-density lipoprotein cholesterol in serum for the first time; the compound can be used for preparing a medicine for reducing total cholesterol in serum, a medicine for reducing triglyceride in serum, a medicine for reducing low-density lipoprotein cholesterol in serum and a medicine for increasing high-density lipoprotein cholesterol in serum, and can be used for preparing medicines for reducing total cholesterol in serum, triglyceride in serum, low-density lipoprotein cholesterol in serum and high-density lipoprotein cholesterol in serum. And an effective new means and a new way are provided for preparing the medicine for preventing or treating the hyperlipemia.

The invention relates to an shRNA (short hairpin Ribonucleic Acid) interference sequence of a targeted silence PCSK9 gene and a construction method and lipid-lowering application of a recombinant adeno-associated virus vector of the shRNA interference sequence. Hyperlipidaemia is a metabolic disease characterized by abnormal rising of cholesterol and triglyceride levels in blood, and the design of lipid-lowering drugs is the focus of attention to improvement of hyperlipidaemia. Proprotein convertase subtilisin / kexin type 9 (PCSK9) can be combined with a low-density lipoprotein receptor (LDL-R) and degrade the LDL-R, so that accumulation of LDL-C in blood is further promoted, and hyperlipidemia is caused. Aiming at the key target PCSK9, a specific shRNA interference sequence is designed, and a recombinant adeno-associated virus vector (rAAV) carrying the sequence is constructed by an enzyme digestion-connection method. In-vitro experiments prove that the vector can remarkably reduce the expression level of PCSK9 protein, so that the cyclic utilization of a low-density lipoprotein receptor (LDL-R) is promoted, and the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma is reduced. The rAAV vector provided by the invention has the characteristics of low production cost, high transfection efficiency, lasting action time and the like, and provides a new thought for gene therapy of hyperlipidemia.

The invention belongs to the technical field of functional microorganisms, and provides pediococcus acidilactici MR21 and application thereof. The pediococcus acidilactici MR21 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 3, 2024, and the preservation number is CGMCC NO. 32896. The pediococcus acidilactici MR21 disclosed by the invention has efficient in-vitro cholesterol removal capacity, excellent safety and remarkable probiotic characteristics, and has the effects of restoring liver functions, reducing liver fat accumulation and regulating expression of fat and cholesterol metabolism related genes by remarkably reducing the content of serum total cholesterol and low-density lipoprotein cholesterol. Therefore, the function of relieving hypercholesterolemia is achieved.

This invention discloses a low-astringency prickly pear lactic acid bacteria fermented beverage and its application in lowering blood lipids and antioxidation, relating to the fields of microbial application and food fermentation technology. The fermented beverage of this invention uses prickly pear juice as raw material and is prepared by fermentation with *Lactobacillus plantarum* R-21. It can significantly reduce the tannin content of prickly pear juice, improve taste, and increase the polysaccharide content and antioxidant properties of the beverage. In vivo experiments show that it can reduce the levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in mouse liver and serum, inhibit fat accumulation and fatty degeneration in liver cells, and enhance the activity of antioxidant enzymes in the liver, demonstrating important application value in lowering blood lipids and antioxidation.

The invention relates to application of an asparagine endopeptidase inhibitor in preparation of a medicine for improving insulin resistance. According to the application, starting from inhibiting the aging driving factor AEP, the AEP inhibitor is tried to be applied to the research of insulin resistance for the first time, and the AEP inhibitor is found to be capable of remarkably improving glucose tolerance and insulin sensitivity. Therefore, the invention provides the application of the asparagine endopeptidase inhibitor in preparation of the medicine for improving insulin resistance. Experiments prove that the AEP inhibitor not only can significantly enhance insulin sensitivity of old mice and improve glucose tolerance, but also can reduce serum low-density lipoprotein cholesterol and lactic dehydrogenase levels, shows multiple improvement effects on glucose metabolism and lipid metabolism, and also can be used for preparing the AEP inhibitor. After long-term administration, obvious toxic and side effects are not found in pathological examinations of blood routine examination, urine routine examination, heart, liver, spleen, lung, kidney and other important organs, so that the traditional Chinese medicine composition is proved to have good safety and is suitable for long-term intervention of chronic diseases.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

The invention discloses application of a group of blood nutrition markers in prediction of central nervous system (CNS) injury function prognosis. According to the technical scheme, the method is characterized in that serum albumin, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) are determined as independent predictive factors of CNS injury prognosis for the first time through retrospective queue research (n = 404), and clinical decision critical values are determined to be 36.35 g / L, 3.60 mmol / L and 2.13 mmol / L respectively. The detection kit developed on the basis of the discovery can objectively and quantitatively evaluate the prognosis risk of the patient within 24 hours of admission, and is obviously superior to that of a traditional scoring system. According to the method, key technical support is provided for precise nutrition intervention and early rehabilitation strategy formulation of the CNS injury.

The invention belongs to the technical field of functional compositions, and discloses a composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof, and the composition comprises the following raw materials in percentage by mass: 13-28% of ginseng, 18-28% of globe artichoke, 10-27% of pueraria peptide, 7-12% of houttuynia cordata, 7-9% of mulberry, 6-9% of gardenia and 10-29% of collagen composite peptide. The composition can reduce alcohol irritation, relieve alcohol absorption and increase the alcohol content; meanwhile, the liver and stomach are protected; meanwhile, alcohol metabolism is rapid, hangover is prevented, headache, dizziness, nausea and other uncomfortable symptoms caused by alcohol are relieved, and the drunkenness degree is relieved. After the medicine is taken for 2-6 months, mild fatty liver and moderate fatty liver can be obviously improved, and severe fatty liver and alcoholic liver can be obviously improved; indexes related to endocrine metabolism, such as blood sugar, blood fat, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, are obviously improved.

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH) and / or atherosclerotic cardiovascular disease (ASCVD), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

The invention discloses a preparation method of torreya grandis gel candies with an effect of reducing total cholesterol. The invention belongs to the technical field of functional food, the Chinese torreya oil and the flaxseed oil have a synergistic effect, and after the Chinese torreya oil and the flaxseed oil are compounded, the blood fat metabolism can be effectively regulated, the total cholesterol level can be reduced, and the content of high-density lipoprotein cholesterol can be increased; the Chinese torreya oil is extracted through a low-temperature pressing process, the linseed oil is prepared through a cold pressing process, active components in the raw materials are reserved to the maximum extent, and meanwhile, the stability and uniformity of functional components in the product are ensured by combining a feeding pump filtering process and a rolling die shaping process; by optimizing the formula and the preparation process of the gel matrix, the product has good elasticity and chewing feeling, is convenient to carry and take and is suitable for daily use. The health-care food does not contain artificially synthesized additives, all the raw materials are natural sources, and the health-care food is suitable for patients with hypercholesterolemia and crowds needing to regulate blood fat, and has relatively high safety and market promotion value.

This invention discloses a *Lactobacillus plantarum* YBE2 and its applications. The *Lactobacillus plantarum* provided by this invention, which produces a high amount of extracellular polysaccharides primarily composed of rhamnose, can simultaneously degrade different types of bile salts, including specifically hydrolyzing glycocholic acid. It also exhibits cholesterol-lowering and acute inflammation-relieving effects. Furthermore, *Lactobacillus plantarum* YBE2 can reduce fat deposition in the abdomen of caged broilers, increase intramuscular fat, promote fatty acid deposition in muscles, and reduce plasma total bile acids, triglycerides, and low-density lipoprotein cholesterol. This significantly improves lipid metabolism and muscle quality in poultry, and can be widely applied in caged broiler farming to promote healthy poultry farming and improve farming efficiency.

The invention relates to a quality control liquid for low-density lipoprotein cholesterol and a preparation method of the quality control liquid. The quality control liquid comprises the following components in percentage by weight: 90-95% of defatted bovine serum, 0.005-0.05% of a cholesterol solution purified by ultracentrifugation, 1-3% of trehalose, 0.2-0.4% of EDTA-2K, 0.02-0.05% of vitamin E, 0.08-0.12% of a liquid biological preservative and 0.1-0.2% of glutathione. The invention has the following beneficial effects: 1, trehalose and vitamin E have a synergistic effect, and the stability at normal temperature reaches more than 12 months (CV is less than 3%); 2, a direct detection method, a precipitation method and a calculation method are adapted, and the deviation with a clinical sample is less than 5%; 3, the synthetic matrix reduces the risk of biogenic pollution, and is suitable for an automatic detection platform.

The invention discloses a roxburgh rose lactic acid bacteria solid beverage and application thereof in preparation of foods, health-care products or medicines for reducing hyperlipidemia, preventing colitis and resisting oxidation, and belongs to the field of probiotic health-care foods. The rosa roxburghii tratt lactic acid bacteria solid beverage is prepared from plant lactobacillus R-15, rosa roxburghii tratt fine powder, mannan oligosaccharide, resistant dextrin, coix lacryma-jobi extract, hawthorn extract, silicon dioxide and the like. The rosa roxburghii tratt lactobacillus solid beverage can significantly reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in the liver and serum of a mouse, inhibit fatty degeneration of the liver, and inhibit colitis induced by high fat diet. The invention has important application value in prevention and treatment of hyperlipidemia and colitis.

This invention relates to a traditional Chinese medicine composition, specifically a traditional Chinese medicine composition for treating diabetic nephropathy, belonging to the fields of medicine and health products. The traditional Chinese medicine composition of this invention is made from components comprising the following raw materials: yam, salvia miltiorrhiza, rosehip, turtle shell, cornus officinalis, dioscorea hypoglauca, cuscuta chinensis, oyster shell, and American ginseng. Through rational formulation, this traditional Chinese medicine composition utilizes the principle of clearing heat and removing dampness, with the synergistic effect of multiple drugs, to significantly reduce fasting blood glucose, improve glucose metabolism, lower low-density lipoprotein cholesterol and triglycerides, and raise high-density lipoprotein cholesterol to regulate lipid metabolism, reduce weight, and has no significant damage to liver and kidney function, with minimal side effects.

The application belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA is used as a biomarker or target to prepare reagents for disease prediction, screening or diagnosis, and to prepare drugs for preventing or treating diseases. Inhibition or destruction of THADA function has the purposes of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, not affecting high-density cholesterol levels, reducing liver triglyceride deposition and liver steatosis, and improving atherosclerosis, and the effect is clear and effective and has no adverse reactions. The application provides a new biomarker and treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

The invention relates to the field of intelligent medical treatment, in particular to a pregnancy disease risk prediction method and device based on biochemical indexes and a program product. Comprising the following steps: S1, acquiring serum biochemical index data of a pregnant woman; s2, comparing the serum biochemical indexes with a preset threshold value; the serum biochemical indexes include aspartate aminotransferase, total protein, albumin, lactic dehydrogenase, alkaline phosphatase, total bile acid, creatine kinase, blood sugar, urea nitrogen, uric acid, creatinine, glomerular filtration rate, potassium, chlorine, total calcium, serum magnesium, inorganic phosphorus, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and homocysteine. When one or more of the myoglobin, the hypersensitive troponin I, the prealbumin, the cystatin C and the creatine kinase isoenzyme MB are abnormal, judging that the pregnancy eclampsia exists. The method is simple, convenient and rapid to operate and low in cost, can be clinically popularized to predict the health state of the pregnant woman on a large scale, and has good clinical value.

A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein phospholipase and / or sphingomyelinase is / are allowed to act on a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.

The invention relates to the field of food, in particular to meal replacement powder for reducing blood fat and preventing cardiovascular and cerebrovascular diseases. The meal replacement powder capable of reducing blood fat and preventing cardiovascular and cerebrovascular diseases comprises the following components in parts by weight: 30-45 parts of coix seed and red bean composite powder, 10-15 parts of konjac powder, 10-15 parts of oat bran, 15-20 parts of pumpkin seeds, 7-10 parts of black sesame, 5-15 parts of a mulberry leaf and hawthorn extract, 3-12 parts of corn resistant dextrin and 0.5-5 parts of composite prebiotics. According to the meal replacement powder capable of reducing blood fat and preventing cardiovascular and cerebrovascular diseases, through the synergistic effect of various natural components, the levels of total cholesterol, low-density lipoprotein cholesterol and triglyceride are remarkably reduced, meanwhile, the level of high-density lipoprotein cholesterol is improved, the meal replacement powder shows a remarkable blood fat reducing effect in SD rat experiments, and the meal replacement powder is suitable for being used for preventing cardiovascular and cerebrovascular diseases. Through the synergistic effect of various mechanisms of inhibiting cholesterol synthesis, promoting cholesterol discharge, improving intestinal health and the like, the blood fat level is effectively improved.

The invention belongs to the technical field of medical risk assessment, and provides a fibrosis metabolism related steatohepatitis risk assessment system. Comprising a data acquisition module configured to determine candidate prediction indexes; the primary screening module is configured to perform single-factor logistic regression analysis on the candidate prediction indexes to determine key prediction indexes of fibrosis metabolism related steatohepatitis; the secondary screening module is configured to screen out four independent predictive factors from key predictive indexes of fibrosis metabolism related steatohepatitis through stepwise multiple regression analysis; and the model training module is configured to train the constructed multi-factor logistic regression model based on the screened four independent predictive factors. According to the method, four indexes of aspartate transaminase, alanine transaminase, triglyceride and high-density lipoprotein cholesterol are integrated, a fibrosis MASH evaluation and prediction model for obese people is constructed, and the evaluation performance is better.

This invention discloses an oil composition with a balanced fatty acid ratio and lipid-lowering effects, and its applications. The oil composition comprises vegetable oil, probiotics, phospholipids from camellia seed cake, gelatin, and sodium alginate. It effectively reduces serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels while increasing high-density lipoprotein cholesterol levels, exhibiting a good lipid-lowering effect. Furthermore, when the oil composition is formulated into microcapsules, it exhibits good stability, encapsulation efficiency, and release rate. The oil composition also helps maintain the activity of probiotics, allowing for better preservation and efficacy. Based on this, this invention also provides a candy containing the oil composition, enriching the variety of products with lipid-lowering effects and promoting the development of lipid-lowering related products.

The application discloses a polysaccharide composition for treating hyperlipidemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing Vansant yellow, Inonotus hispidus and Sarcodon fuligineus and then extracting with water. The polysaccharide composition can inhibit the increase of body weight and blood sugar of hyperlipidemia mice, reduce fat vacuolization and fat index, reduce the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increase the content of high-density lipoprotein cholesterol, and regulate the composition and abundance of intestinal flora to improve the intestinal flora disorder phenomenon, and the effect is better than that of single polysaccharide, thereby providing a new direction for the treatment of auxiliary blood sugar reduction.

Method of lowering low-density lipoprotein cholesterol or preventing a cardiac event in a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent, involving administering to the subject a prophylactically effective amount of an RNAi agent. Also, a method of preventing development of atherosclerotic cardiovascular disease in a subject involving administering to the subject a prophylactically effective amount of an RNAi agent. Further, a method of treating a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent involving administering to the subject a therapeutically effective amount of an RNAi agent.

The invention belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA as a biomarker or a target can be used for preparing a reagent for predicting, screening or diagnosing diseases and preparing a medicine for preventing or treating the diseases. The traditional Chinese medicine composition has the functions of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels in vivo, not influencing the high-density cholesterol level, reducing liver triglyceride deposition and liver fatty degeneration and improving atherosclerosis, the effect is definite and effective, and no adverse reaction exists. The invention provides a new biomarker and a treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

The application discloses a kind of traditional Chinese medicine preparation for treating hyperlipidemia, which is prepared from the following raw medicinal materials: radix codonopsis 10-20 g, astragalus 25-35 g, gynostemma pentaphyllum 10-20 g, atractylodes 10-20 g, zanthoxylum 3-8 g, monascus 10-15 g, and galangal 10-20 g. When treating, it is orally taken, one dose per day, taken twice, taken half an hour after breakfast and dinner, and continuously taken for 4 weeks as a treatment course. The traditional Chinese medicine preparation for treating hyperlipidemia has the advantages that it is helpful to improve hyperlipidemia, and the serum total cholesterol, triglyceride, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and other indicators of patients after treatment are obviously better than those of the control group (oral atorvastatin), with statistical significance (P<0.05). The traditional Chinese medicine preparation for treating hyperlipidemia has the advantages of remarkable curative effect, good safety, low price and simple prescription, and has high clinical popularization value.

The invention relates to the technical field of detection reagent preparation, and discloses a stable oxidized low-density lipoprotein cholesterol detection kit and a preparation method thereof.The kit is composed of a component R1 and a component R2, the component R1 at least comprises a buffer solution, a sensitizer, a surfactant, a stabilizer, an anti-interference agent and a preservative, and the component R2 at least comprises a buffer solution, a sensitizer, a surfactant, a stabilizer, an anti-interference agent and a preservative; the component R2 at least comprises an ion buffer solution, a stabilizer, a sealing agent, an antibody-carboxyl microsphere conjugate and a preservative; the antibody-carboxyl microsphere conjugate is a conjugate of an oxidized low-density lipoprotein antibody and carboxyl microspheres. According to the formula of the oxidized low-density lipoprotein reagent composition, the reagent R1 and the reagent R2, the production cost is effectively reduced, the oxidized low-density lipoprotein reagent composition can be used on a full-automatic biochemical analyzer, the automation degree is high, compared with similar products, the oxidized low-density lipoprotein reagent composition has higher accuracy, repeatability and stability, and unexpected technical effects are achieved.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

This invention provides the use of RNA interferants that inhibit PCSK9 synthesis in prophylactic or therapeutic methods. [Solution] A method for reducing low-density lipoprotein cholesterol or preventing cardiac events in a subject having atherosclerotic cardiovascular disease or being at equivalent risk to atherosclerotic cardiovascular disease, comprising the step of administering a prophylactic effective amount of RNAi to the subject. Also, a method for preventing the onset of atherosclerotic cardiovascular disease in a subject, comprising the step of administering a prophylactic effective amount of RNAi to the subject. Furthermore, a method for treating a subject having atherosclerotic cardiovascular disease or being at equivalent risk to atherosclerotic cardiovascular disease, comprising the step of administering a therapeutic effective amount of RNAi to the subject.

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

The invention discloses a polysaccharide composition for treating chronic alcoholic liver injury and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is prepared by crushing phellinus linteus linteus, bolete, morchella and cordyceps militaris, mixing the crushed materials according to a mass ratio of 4: 2: 2: 2, performing water ultrasonic extraction, and performing hot water extraction. The polysaccharide composition can reduce fat vacuolation and hepatocyte swelling in the liver, inhibit expression of liver function related enzymes such as ALT and AST, improve secretion of blood fat such as total cholesterol, triglyceride and high-density lipoprotein cholesterol and reduce expression of inflammatory factors such as IL-1beta and TNF-alpha in the liver, and the effect of the polysaccharide composition is better than that of single polysaccharide. The polysaccharide composition can relieve liver injury caused by long-term drinking and achieve the effects of dispelling the effects of alcohol and protecting the liver.